Agilent Agrees to Buy Proscia for $240M
Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.
How this was made
The 30-second read
Why it matters
The deal adds recurring‑revenue software to Agilent’s portfolio, potentially enhancing cross‑sell opportunities but also introducing integration risk.
Market read
First‑report M&A news for a large‑cap company; likely to move Agilent’s stock on announcement.
What to watch
Potential earn‑out uncertainty and the lack of disclosed revenue multiples for Proscia may affect investor perception.
Background
Agilent, a leading life‑sciences and diagnostics company, is expanding into digital pathology software through the Proscia acquisition.
Ticker impact
Agilent announced agreement to acquire Proscia for $240M cash with up to $30M earn‑out.
likely pressure as the market prices in the $240M cash outlay and integration risk
Large‑cap M&A news typically moves the acquirer’s stock; the deal size and strategic fit suggest modest short‑term impact.
Market effects
Adds a software component to Agilent's diagnostics, potentially prompting other life‑sciences firms to consider similar acquisitions.
U.S. life‑sciences sector may see modest re‑rating as the deal highlights consolidation trends.
Limited to the diagnostics and digital pathology niche; broader market impact minimal.
Counterpoint
The integration risk and high multiple could weigh on Agilent’s valuation, suggesting a short‑term downside.
Key entities
- CompanyAgilent Technologies
US‑listed life‑sciences and diagnostics firm (ticker A).
- CompanyProscia
Private digital pathology software provider.
